New study: ‘The Corporate Reputation of Pharma in 2014 – the Patient Perspective’
13 February 2015 | By PatientView
An independent study by PatientView...
List view / Grid view
13 February 2015 | By PatientView
An independent study by PatientView...
2 February 2015 | By CPhI Worldwide
Experts from CPhI Worldwide have shared their pharma predictions for 2015, suggesting that Continuous Manufacturing and QbD will expand, with FDA becoming ‘industry tutor’. However, pharma concerns about supply chain persist...
21 January 2015 | By GlobalData
With the US Food and Drug Administration (FDA) approving an all-time record number of orphan drugs during 2014, the pricing of these treatments is set to come under increased scrutiny, says an analyst with research and consulting firm GlobalData...
11 December 2014 | By GlobalData
Pharmaceutical companies will suffer an estimated $65 billion drop in sales by 2019 due to the patent expiries of several leading drugs, according to research and consulting firm GlobalData...
24 November 2014 | By BioM Biotech Cluster Development GmbH
Munich is the top location for biotechnology and pharmaceutical industries according to a new study by the Chamber of Industry and Commerce (IHK)...
19 November 2014 | By The Access to Medicine Index
The world’s leading pharmaceutical companies are doing more to improve access to medicine in developing countries, with a raft of new initiatives, scale-ups and innovations over the last two years...
Leader in contract bio/pharma industry intelligence predicts ongoing in-house manufacture...
19 February 2014 | By Allen L. Burgenson, Manager - Regulatory Affairs, Lonza Walkersville, Inc
Allen L. Burgenson, Manager - Regulatory Affairs, Lonza Walkersville, Inc answers the question “From a vendor perspective, do you conclude that Big Pharma is still actively engaging in outsourcing of the activities that you have expertise in?”